Table 3.
Serum levels of sCD23 and galectin-3 are modulated in various pathologies
| Pathology | sCD23 | Galectin-3 |
|---|---|---|
| Cancer | Chronic lymphocytic leukemia ↑a Pancreatic cancer ↑ AIDS-associated Non-Hodgkin’s lymphoma ↑ Glioma ↓b |
Thyroid cancer ↑ [125–127] c Melanoma ↑ [128–130] Colorectal Cancer ↑ [128] Head and neck squamous cell carcinomas ↑ [131] Bladder cancer ↑ [132] Breast and Ovarian cancer ↑ [128] Non-Hodgkin’s lymphoma ↑ [128] |
| Auto-immune diseases | Arthritis ↑ and ↓ Systemic lupus erythematosus ↑ [133] Primary Sjogren’s disease ↑ [133] Autoimmune thyrioditis ↑ [134] Myasthenia gravis ↑ [134,135] Crohn’s disease ↓ [134] |
Rheumatoid arthritis ↑ [136,137] Systemic lupus erythematosus ↑ [137] Behçet’s disease ↑ [137] Inflammatory bowel disease ↑ [138] |
| Allergic diseases | Asthma ↑ Atopic dermatitis ↑ |
|
| Other | Chronic heart failure ↑ [123,139–141] Liver fibrosis ↑ Pulmonary fibrosis ↑ |
a
↑ serum levels are found to be upregulated
b
↓ serum levels are found to be downregulated
c
References are given only if not cited in the text